Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053898 · ClinicalTrials.gov registry record · Phase 3
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,104
- Enrollment target
NCT00053898 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 3,104 participants.
The verdict
NCT00053898, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,104 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production. It is not yet known whether anastrozole is more effective than tamoxifen in preventing the recurrence of breast cancer. PURPOSE: This randomized phase III trial is studying anastrozole to see how well it works compared to tamoxifen in preventing the recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ who are undergoing lumpectomy and radiation therapy.
Interventions
- RADIATION Radiation Therapy
- DRUG anastrozole
- DRUG tamoxifen citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,104 participants |
| Start Date | 2003-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053898
The ClinicalTrials.gov registry entry for NCT00053898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT00053898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053898 about?
NCT00053898 is a clinical study titled "Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Tamoxifen may fight breast cancer by blocking the use of estrogen. Anastrozole may fight breast cancer by decreasing estrogen production. It is not yet known whether anastrozole is more effective than tamoxifen in preventing the re...
What is the current status of trial NCT00053898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,104 participants. The study started on 2003-01. Estimated completion is 2016-05.
What interventions are being tested in trial NCT00053898?
The interventions under investigation include: Radiation Therapy (RADIATION), anastrozole (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00053898?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.